Señales en vivo de KMDA.TA | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 07:32):

Stats
Volumen de hoy	11 727.00
Volumen promedio	42 096.00
Capitalización de mercado	1.21B
EPS	ILA0.0600 ( 2023-11-13 )
Próxima fecha de ganancias	( ILA0.0600 ) 2024-05-08
Last Dividend	ILA0 ( N/A )
Next Dividend	ILA0 ( N/A )
P/E	37.64
ATR14	ILA7.55 (0.36%)

Kamada Ltd. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kamada Ltd. Finanzas

Annual	2023
Ingresos:	ILA142.52M
Beneficio Bruto:	ILA55.49M (38.94 %)
EPS:	ILA0.170

FY	2023
Ingresos:	ILA142.52M
Beneficio Bruto:	ILA55.49M (38.94 %)
EPS:	ILA0.170

FY	2022
Ingresos:	ILA129.34M
Beneficio Bruto:	ILA46.70M (36.11 %)
EPS:	ILA-0.0518

Financial Reports:

No articles found.

Kamada Ltd.

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Actualizaciones en tiempo real para Kamada Ltd. [KMDA.TA]

Upcoming Earnings Alert